Reviving the Mitochondria: A Hopeful Horizon in Refractory Heart Failure

Refractory heart failure (HF) remains a pressing clinical challenge despite substantial progress in pharmacologic and device-based interventions. While current therapies target neurohormonal, hemodynamic, and metabolic derangements, a crucial element of cellular dysfunction often remains overlooked: mitochondrial health. Mitochondrial dysfunction plays a central role in the pathogenesis and progression of HF, contributing to bioenergetic failure, oxidative stress, and cardiomyocyte death. Recent advances in mitochondrial-targeted therapies have opened new possibilities for treating HF at its energetic roots. This editorial explores the pathophysiological role of mitochondria in HF, reviews emerging therapeutic strategies aimed at restoring mitochondrial function, and outlines key challenges that must be addressed to translate these innovations into clinical practice.